CardiAMP vs HucMSC intramyocardial therapy

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Heart Failure

Shared mechanism: Cardiac cell therapy · full Heart Failure pipeline

CardiAMP

Developed by BioCardia

Phase 3 in Heart FailureCell therapy (autologous)
Partial signal

NCT02438306 · Phase 3 · completed

The study randomized 125 participants to CardiAMP or a sham procedure and masked participants and outcome assessors. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: April 2027 · NCT06258447 (registry estimate)

Reported efficacy

A composite endpoint based on a 3-tiered Finkelstein-Schoenfeld (FS) hierarchical analysis. (12 Months): 3-tiered Finkelstein-Schoenfeld primary endpoint at 12 months (interim, 102 of eventual 125 patients): Tier 1 all-cause death 5.6% CardiAMP vs 5.3% control (P=.42); Tier 2 MACCE 16.7% vs 15.8% (P=.82); Tier 3 6MWT change +36.1m vs +33.4m (P=.6) - none reached significance; DSMB futility review concluded the trial was unlikely to meet its primary endpoint (missed)

Result source: NCT02438306

HucMSC intramyocardial therapy

Developed by Tasly Pharmaceutical Group

Phase 1/2 in Heart FailureCell therapy (MSC)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2026 · NCT07265349 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Heart Failure

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointCardiAMPHucMSC intramyocardial therapy
CV death or HF hospitalisation—Not posted · NCT02438306—Not reported
HF hospitalisation—Not posted · NCT02438306—Not reported
CV death—Not posted · NCT02438306—Not reported
KCCQ clinical summary, change—Not posted · NCT02438306—Not reported

CV death or HF hospitalisation

CardiAMP
—Not posted · NCT02438306
HucMSC intramyocardial therapy
—Not reported

HF hospitalisation

CardiAMP
—Not posted · NCT02438306
HucMSC intramyocardial therapy
—Not reported

CV death

CardiAMP
—Not posted · NCT02438306
HucMSC intramyocardial therapy
—Not reported

KCCQ clinical summary, change

CardiAMP
—Not posted · NCT02438306
HucMSC intramyocardial therapy
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

HucMSC intramyocardial therapy: no structured comparison results are available for Heart Failure.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

CardiAMP

All-cause Mortality 5.6% vs 5.3% control @ 51.96wk
absolute value · percentage points
NCT02438306 · Phase 3 · sponsor-reported, not registry data
CV Death MI UA Revascularization or Stroke Composite 16.7% vs 15.8% control @ 51.96wk
event count · % of participants
NCT02438306 · Phase 3 · sponsor-reported, not registry data

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: CardiAMP's landscape · HucMSC intramyocardial therapy's landscape